Table 1 SARS-CoV-2 mAbs in clinical development

From: COVID-19 antibodies on trial

Sponsor Product Clinical stage Trial ID Study
Regeneron/NIAID REGN-COV2 (REGN10933 + REGN10987; human IgG1 mAbs targeting S protein epitope) Phase 2/3 NCT04452318 2,000 healthy adults with infected people in household
Regeneron/NIAID REGN-COV2 Phase 2/3 NCT04426695 2,970 hospitalized adults with COVID-19
Regeneron/NIAID REGN-COV2 Phase 1/2 NCT04425629 2,104 ambulatory patients with COVID-19
AbCellera/Eli Lilly/NIH LY3819253 or LY3819253 + LY3832479 (human IgG1 mAbs targeting S protein epitope) Phase 3 NCT04427501 800 patients with mild to moderate COVID-19
AbCellera/Eli Lilly/NIH LY3819253 or LY3819253 + LY3832479 Phase 3 NCT04497987 2,400 healthy staff or residents of skilled nursing facilities
AbCellera/Eli Lilly/NIH LY3819253 versus remdesivir (small-molecule nucleotide analog antiviral that blocks viral RNA polymerase) Phase 3 NCT04501978 10,000 hospitalized patients
Vir Biotechnology/GlaxoSmithKline VIR-7831/GSK4182136 (human IgG1 mAb targeting S protein epitope) Phase 3 NCT04545060 1,360 non-hospitalized patients with COVID-19 at high risk
BeiGene/Singlomics/Peking University BGB-DXP593 (human IgG1 mAb targeting S protein epitope) Phase 2 NCT04551898 180 patients with mild to moderate COVID-19
BeiGene/Singlomics/Peking University BGB-DXP593 Phase 1 NCT045332294 30 healthy adults 18–60 years olds
Junshi Biosciences/Institute of Microbiology, Chinese Academy JS016 (human mAb targeting S protein epitope) Phase 1 NCT04441918 40 healthy participants 15–45 years old
Tychan TY027 Phase 1 NCT04429529 32 healthy adults 21–50 years old
Celltrion CT-P59 (human mAb targeting S protein epitope) Phase 1 NCT04525079 32 healthy adults 19–55 years old
Brii Bio/TSB Therapeutics/Tsinghua University BRII-196 (human mAb targeting S protein epitope) Phase 1 NCT04479631 12 healthy adults 18–49 years old
Brii Bio/TSB Therapeutics/Tsinghua University BRII-198 (human mAb targeting S protein epitope) Phase 1 NCT04479644 12 healthy adults 18–49 years old
Sinocelltech/Chinese Academy of Sciences SCTA01 (humanized mAb targeting S protein epitopes) Phase 1 NCT04483375 33 healthy adults
Mabwell (Shanghai) Bioscience MW33 (human mAb targeting S protein epitope) Phase 1 NCT05433048 42 healthy adults 18–45 years old
Sorrento/Mount Sinai COVI-GUARD/STI-1499 (human mAb targeting S1 subunit of S protein) Phase 1 NCT04454398 33 hospitalized patients with moderate COVID-19
AstraZeneca/Vanderbilt AZD8895 + AZD1061 (IgG1 human mAbs targeting S protein epitopes) Phase 1 NCT04507256 48 healthy adults 18–55 years old
Hengenix Biotech HLX70 (human mAb targeting S protein epitope) Phase 1 NCT04561076 24 healthy adults 18–60 years old
  1. Source: https://www.antibodysociety.org/covid-19-biologics-tracker/